Sarepta Therapeutics, a pioneer in genetic medicines for rare neuromuscular diseases, experienced a pronounced revenue drop in 2025 to $443 million, down nearly 77% year-over-year, alongside an operating loss of $700 million and net loss exceeding $412 million [F1]. This reversal from prior growth years stems largely from safety concerns around its ELEVIDYS gene therapy and complications related to regulatory approvals and reimbursements [S1][S2][N7]. The company is executing a major restructuring plan including workforce cuts and portfolio reprioritization to reduce expenses while investing selectively to validate long-term clinical benefits [S4][N6]. Sarepta’s sustainability depends on resolving confirmatory trial outcomes under FDA accelerated approval pathways and navigating intensifying healthcare pricing pressures and regulatory complexities [S4][S8].